Motley Fool Australia
  •  
  • Log Out
  • Menu
  1. Stocks
    2. /
  2. Neuren Pharmaceuticals Ltd (ASX: NEU)
    3. /

Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News

Price

$10.57

Movement

0.24 (-2.22%)

As at 3 Apr - Closed (20 mins delayed)

52 Week Range

$10.75 - $24.00

 
1 Year Return

-48.19%

Neuren Pharmaceuticals Ltd Chart and Price Data

2025
2025
2025
2025
$10
$15
$20
$10
$15
$20
$10
$15
$20
$10
$15
$20

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.38 billion
P/E Ratio 10.98
Dividend Yield 0.00%
Shares Outstanding 129.26 million
Earnings per share 0.915
Dividend per share N/A
Year To Date Return -4.56%
Earnings Yield 9.10%
Franking -
Earnings Yield

9.10%

Franking

-

Dividend per share

N/A

Year To Date Return

-4.56%

Shares Outstanding

129.26 million

Earnings per share

0.915

Share Price

$10.57

Day Change

0.24 (-2.22%)

52 Week Range

$10.75 - $24.00

Yesterday's Close

$10.81

Today's Open

$10.82

Days Range

$10.55 - $10.92

Volume

914,762

Avg. Volume (1 month)

651,911

Turnover

$9,778,205

As at 3 Apr - Closed

Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News

A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
Broker Notes

These ASX 200 shares could rise ~40% to 75%

| James Mickleboro

Brokers are tipping these shares to rocket. But why?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

| Sebastian Bowen

The ASX 200 finished the trading week on a high.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Healthcare Shares

4 ASX healthcare stocks having a cracking run on Friday

| James Mickleboro

These shares are making their shareholders smile on Friday. What's happening?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Two up, one down: ASX healthcare stocks split after FY24 results

| Zach Bristow

The love wasn't shared evenly for these healthcare players today.

Read more »

A group of people at a party look upwards to the camera as they celebrate the rise of ASX value shares
Share Market News

Ten-baggers galore! These 19 top ASX stocks returned 1,000% or more in just 10 years

| Bernd Struben

The ASX is one of the best stock markets in the world to find those illustrious ten-baggers.

Read more »

A man sees some good news on his phone and gives a little cheer.
Broker Notes

These ASX shares could rise 20% to 60%

| James Mickleboro

Analysts see major upside potential for these stocks.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Light & Wonder, Neuren, Nick Scali, and QBE shares are falling today

| James Mickleboro

These shares are having a tough session on Friday. But why?

Read more »

Health professional working on his laptop.
Healthcare Shares

Why are Neuren Pharmaceuticals shares crashing 9%?

| James Mickleboro

The market may be storming higher but this biotech stock isn’t. But why?

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Best Shares

Which ASX 200 market sector has been the best performer over 10 years?

| Bronwyn Allen

This might surprise you...

Read more »

A person sitting at a desk smiling and looking at a computer.
Broker Notes

3 ASX shares poised to rise 50% by 2025

| Zach Bristow

In a volatile market, these names could outshine next year.

Read more »

A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt
Healthcare Shares

This ASX 200 healthcare share is frozen amid 'slower than expected' growth

| Zach Bristow

Investors have a bit to digest after today's updates.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

This ASX stock could rise 60%+

| James Mickleboro

Bell Potter sees major upside for this buy-rated stock. But why?

Read more »

Frequently Asked Questions

NEU ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
3rd Apr 2025 2025-04-03T08:21:53 Notification of cessation of securities - NEUYesNo8:21am413k
3rd Apr 2025 2025-04-03T07:56:22 Update - Notification of buy-back - NEUYesNo7:56am616k
3rd Apr 2025 2025-04-03T07:53:42 Appendix 4GYesNo7:53am12281k
3rd Apr 2025 2025-04-03T07:51:47 2024 Annual Report to shareholdersYesNo7:51am601.9M
2nd Apr 2025 2025-04-02T08:31:06 Update - Notification of buy-back - NEUYesNo8:31am616k
1st Apr 2025 2025-04-01T08:49:15 Update - Notification of buy-back - NEUYesNo8:49am616k
31st Mar 2025 2025-03-31T09:06:08 Update - Notification of buy-back - NEUYesNo9:06am616k
28th Mar 2025 2025-03-28T08:55:42 Update - Notification of buy-back - NEUYesNo8:55am616k
27th Mar 2025 2025-03-27T09:36:16 Neuren initiates development of NNZ-2591 to treat HIEYesNo9:36am2169k
27th Mar 2025 2025-03-27T08:55:51 Update - Notification of buy-back - NEUYesNo8:55am616k

About Neuren Pharmaceuticals Ltd

Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. 

In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.

Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi. 

Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.

NEU Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 Apr 2025 $10.81 $-0.54 -4.76% 922,800 $11.38 $11.48 $10.75
01 Apr 2025 $11.35 $-0.58 -4.86% 561,275 $11.90 $11.98 $11.30
31 Mar 2025 $11.93 $-0.33 -2.69% 703,012 $11.89 $12.11 $11.41
28 Mar 2025 $12.26 $0.25 2.08% 435,076 $11.86 $12.40 $11.82
27 Mar 2025 $12.01 $0.08 0.67% 628,767 $12.00 $12.43 $11.82
26 Mar 2025 $11.93 $-0.69 -5.47% 999,532 $12.90 $12.94 $11.80
25 Mar 2025 $12.62 $0.15 1.20% 689,962 $12.47 $12.78 $12.14
24 Mar 2025 $12.47 $-0.08 -0.64% 299,851 $12.51 $12.71 $12.34
21 Mar 2025 $12.55 $-0.05 -0.40% 416,984 $12.50 $12.82 $12.50
20 Mar 2025 $12.60 $0.34 2.77% 564,722 $12.25 $12.75 $12.25
19 Mar 2025 $12.26 $-0.04 -0.33% 439,719 $12.05 $12.28 $11.98
18 Mar 2025 $12.30 $0.24 1.99% 497,246 $12.21 $12.54 $11.98
17 Mar 2025 $12.06 $0.38 3.25% 628,421 $11.93 $12.15 $11.60
14 Mar 2025 $11.68 $0.65 5.89% 600,734 $11.01 $11.74 $11.01
13 Mar 2025 $11.03 $-0.07 -0.63% 633,924 $11.25 $11.39 $11.03
12 Mar 2025 $11.10 $-0.30 -2.63% 823,492 $11.28 $11.40 $11.07
11 Mar 2025 $11.40 $-0.73 -6.02% 828,176 $11.75 $11.76 $11.26
10 Mar 2025 $12.13 $-0.15 -1.22% 445,288 $12.28 $12.58 $12.13
07 Mar 2025 $12.28 $-0.31 -2.46% 504,700 $12.32 $12.50 $12.20
06 Mar 2025 $12.59 $0.16 1.29% 1,198,634 $12.60 $12.73 $12.27
05 Mar 2025 $12.43 $0.10 0.81% 742,613 $12.28 $12.49 $12.06
04 Mar 2025 $12.33 $-0.88 -6.66% 758,906 $12.85 $12.94 $12.33

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
16 Aug 2024 Joseph(Joe) Basile Buy 6,406 $100,766
On-market trade.
11 Jun 2024 Joseph(Joe) Basile Buy 5,000 $97,450
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Dianne Margaret Angus Non-Executive Director Jul 2018
Mr Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over twenty five years' experience in ASX and NASDAQ listed companies, she has expertise in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
Mr Jonathan (Jon) Charles Pilcher Chief Executive OfficerManaging Director Aug 2013
Mr Pilcher was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
Dr Jenny Lee Harry Non-Executive Director Jul 2018
Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry. Jenny is a CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Board's of listed and unlisted companies and on the Board's IP sub-committee of the Children's Medical Research Institute.
Mr Patrick Davies Non-Executive DirectorNon-Executive Chairman Jul 2018
Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides advice to healthcare businesses and investors.
Mr Joseph(Joe) Basile Non-Executive Director Mar 2023
Mr Basile has held executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales roles in Australia and Asia.
Ms Lauren Frazer Chief Financial OfficerCompany Secretary Aug 2020
-
Lauren Frazer Chief Financial OfficerCompany Secretary
-
Liza Squires Chief Medical Officerf
-
Larry Glass Chief Science Officer
-
Gerry Zhao Vice President Corporate Development
-
Clive Blower Vice President Product Development
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 22,507,287 17.65%
J P Morgan Nominees Australia Pty Limited 12,099,419 9.49%
Citicorp Nominees Pty Limited 11,687,108 9.17%
National Nominees Limited 4,166,698 3.27%
Cameron Richard Pty Ltd 4,123,084 3.23%
Bnp Paribas Noms Pty Ltd 3,584,206 2.81%
Stuart Andrew Pty Ltd 2,633,787 2.07%
Essex Castle Limited 2,387,678 1.87%
Smithley Super Pty Ltd 1,870,000 1.47%
Linwierik Super Pty Ltd 1,761,385 1.38%
Sharesies Australia Nominee Pty Limited 1,435,555 1.13%
Bnp Paribas Nominees Pty Ltd 796,367 0.62%
First Colbyco Pty Ltd 750,000 0.59%
Mjhft Pty Ltd 750,000 0.59%
Bnp Paribas Nominees Pty Ltd Acf Clearstream 745,279 0.58%
Dr Robin Lance Congreve 671,637 0.53%
Hsbc Custody Nominees (Australia) Limited A/C 2 499,399 0.39%
Emancipayte Pty Ltd 470,756 0.37%
Netwealth Investments Limited 421,309 0.33%
Mr He Zhao 405,000 0.32%
Pfizer Inc 404,072 0.32%

Profile

since

Note